THE European Commission has
granted marketing authorisation in
Europe for Sanofi’s Lyxumia
(lisenatide), which is the first oncedaily
prandial GLP-1 receptor
agonist and is indicated for the
treatment of type 2 diabetes.
The approval is for Lyxumia taken
in combination with oral glucosecontaining
medicinal products and/
or basal insulin when these,
together with diet and exercise, do
not provide adequate glycaemic
control.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Feb 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Feb 13
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.